Breaking News

Galatea Surgical Announces the Launch of GalaFORM 3D Surgical Scaffold

By Tepha Inc. | May 11, 2017

Product is indicated for soft tissue support and to repair, elevate, and reinforce soft tissue.

Galatea Surgical, a wholly owned subsidiary of Tepha Inc., has received U.S. Food and Drug Administration 510k clearance for its GalaFORM 3D Surgical Scaffold for use in plastic and reconstructive surgery. Based on Tepha’s proprietary P4HB bioresorbable polymer technology, GalaFORM 3D is the only three-dimensionally contoured, surgical scaffold with a reinforcing rim, designed to uplift the body’s natural shape, provide easier placement and reduce procedure time.

Galatea is a Premier Partner of the American Society for Aesthetic Plastic Surgery (ASAPS), and will commercially launch GalaFORM 3D at the upcoming 50th Anniversary meeting of ASAPS in San Diego, Calif. 
“One of the cornerstones of Galatea is our commitment to surgeon and patient education. We are honored to be a Premier Partner of ASAPS, an organization that is focused on providing its members with access to educational and practice development programs," said Andy Joiner, president and CEO of Tepha. "Innovation is an important driver of what we do at Galatea, and we are pleased to be launching GalaFORM 3D, a resorbable scaffold, in conjunction with the 50th anniversary of ASAPS. Galatea is committed to engineering new products that offer significant surgeon and patient benefits and providing access to this new technology to ASAPS and it membership.”
GalaFORM 3D is indicated for soft tissue support and to repair, elevate, and reinforce soft tissue where weakness or voids exist. Galatea has been an innovator in the field of surgical scaffolds for plastic and reconstructive surgery since commencing the clinical evaluation of its GalaFLEX flat mesh in 2011. The launch of the rimmed GalaFORM 3D Surgical Scaffold follows the launch earlier this year of GalaSHAPE 3D, the market’s first 3D surgical scaffold for plastic and reconstructive surgery.
William P. Adams, a Dallas based board certified plastic surgeon commented, “Scaffolds play an important role in aesthetic surgery, where we deal with rejuvenating weakened tissue. We have studied soft-tissue support products through the years, but they are much different; they don’t add long-term tissue strength and aren’t as biocompatible. Galatea scaffolds are made of an easily absorbable monofilament, rather than a multifilament, which reduces infection.  GalaFORM 3D is a novel scaffold with out-of-the-box shape to better fit the patient’s natural curves. I’m looking forward to using this game-changing 3D scaffold in my patients that require soft tissue support.”
Tepha Inc., founded in 1998 and headquartered in Lexington, Mass., supplies medical devices focused on the bioMaterials market. Tepha’s products are designed and developed to elevate, support and reinforce areas of soft tissue weakness as well as to promote improved healing responses. To date, Tepha and its partners have received 23 510(k) clearances for devices marketed in the United States as well as five CE Marks for products sold in Europe. Commercial products based on Tepha’s resorbable P4HB polymer technology include high tensile strength sutures for orthopedic soft tissue repair; mesh constructs for ventral and inguinal hernia repair; monofilament sutures for abdominal wall closure and plastic surgery; patches for tendon and ligament repairs; and mesh constructs used in face and breast lifts. To date, products made from P4HB have been successfully used in more than 1 million surgical procedures worldwide, and have been the subject of over 30 published clinical and scientific papers.
The American Society for Aesthetic Plastic Surgery is recognized as the world's leading organization devoted entirely to aesthetic plastic surgery and cosmetic medicine of the face and body. ASAPS is comprised of more than 2,600 plastic surgeons.
  • Loading Orthopedic Devices with Biologics and Pharmaceuticals

    Loading Orthopedic Devices with Biologics and Pharmaceuticals

    Dr. Kevin Nelson, Founder and CSO, TissueGen Inc.||May 19, 2017
    Fiber technology enables the delivery of the therapeutic components via a biodegradable platform that can be implanted.

  • Looking Beneath the Surface

    Looking Beneath the Surface

    Sam Brusco, Associate Editor||May 19, 2017
    Surface treatments seek to improve orthopedic device usability, longevity, and bone integration.

  • Going to Extremes

    Going to Extremes

    Michael Barbella, Managing Editor||May 19, 2017
    The innovation and market value found in extremity solutions is prompting a change of heart among major orthopedic firms.